Prioritization of Therapeutic Targets of Inflammation Using Proteomics, Bioinformatics, and In Silico Cell–Cell Interactomics

  • Arsalan S. Haqqani
  • Danica B. Stanimirovic
Part of the Methods in Molecular Biology book series (MIMB, volume 1061)


Leukocyte extravasation is a multistep process, involving the movement of leukocytes out of the circulatory system, through vascular endothelium and to the site of tissue damage or infection. Protein–protein interactions play key roles in the extravasation process and have been attractive therapeutic targets for inhibiting inflammation using blocking (or neutralizing) antibodies. These targets include protein–protein interactions between cytokines (or chemokines) and their receptors on leukocytes and between adhesions molecules involving leukocyte–endothelium contacts. A number of therapeutics against these targets are currently used in clinic for treatment of inflammatory disorders, however, they are associated with side-effects partly due to the off-target actions (i.e., nonspecific targets). There is a need for novel targets involved in the leukocyte extravasation process that are specific to leukocyte subsets or to individual inflammatory disorder, and are amenable for drug development (i.e., duggable). In this chapter, we describe a methodology to identify novel “druggable” targets involving protein–protein interactions between activated leukocytes and endothelial cells using a combination of proteomics, bioinformatics and in silico interactomics. The result is a prioritized list of protein–protein interactions in a network consisting of leukocyte–endothelial cell communication and contacts. These prioritized targets can be pursued for the development of therapeutics such as neutralizing antibodies and for their validation through preclinical testing. The method described here provides the workflow to identify and clinically target important cell–cell interactions that are specific/selective for particular inflammatory disorders and to improve currently available therapies.

Key words

Protein–protein interactions Intercellular Target prioritization Therapeutics Inflammation Extravasation Druggable Proteomics Bioinformatics 


  1. 1.
    Brown BA (2009) Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag 5:585–594PubMedCrossRefGoogle Scholar
  2. 2.
    Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F (2012) Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed 83:72–80PubMedGoogle Scholar
  3. 3.
    Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO (2010) Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today 15:656–667PubMedCrossRefGoogle Scholar
  4. 4.
    Rossi B, Constantin G (2008) Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 7:85–93PubMedCrossRefGoogle Scholar
  5. 5.
    Engelhardt B, Wolburg H (2004) Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 34:2955–2963PubMedCrossRefGoogle Scholar
  6. 6.
    Coisne C, Lyck R, Engelhardt B (2007) Therapeutic targeting of leukocyte trafficking across the blood–brain barrier. Inflamm Allergy Drug Targets 6:210–222PubMedCrossRefGoogle Scholar
  7. 7.
    Wittchen ES (2009) Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci 14:2522–2545CrossRefGoogle Scholar
  8. 8.
    Haqqani AS, Stanimirovic DB (2011) Intercellular interactomics of human brain endothelial cells and th17 lymphocytes: a novel strategy for identifying therapeutic targets of CNS inflammation. Cardiovasc Psychiatry Neurol 2011:175364PubMedGoogle Scholar
  9. 9.
    Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275PubMedCrossRefGoogle Scholar
  10. 10.
    Scheinfeld N (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15:280–294PubMedCrossRefGoogle Scholar
  11. 11.
    Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R, Bouthillier A, Becher B, Arbour N, David S, Stanimirovic D, Prat A (2008) Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 9:137–145PubMedCrossRefGoogle Scholar
  12. 12.
    Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872–1874PubMedGoogle Scholar
  13. 13.
    Stanimirovic D, Shapiro A, Wong J, Hutchison J, Durkin J (1997) The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol 76:193–205PubMedCrossRefGoogle Scholar
  14. 14.
    Haqqani AS, Kelly J, Baumann E, Haseloff RF, Blasig IE, Stanimirovic DB (2007) Protein markers of ischemic insult in brain endothelial cells identified using 2D gel electrophoresis and ICAT-based quantitative proteomics. J Proteome Res 6:226–239PubMedCrossRefGoogle Scholar
  15. 15.
    Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13:1173–1175PubMedCrossRefGoogle Scholar
  16. 16.
    Palagi PM, Walther D, Quadroni M, Catherinet S, Burgess J, Zimmermann-Ivol CG, Sanchez JC, Binz PA, Hochstrasser DF, Appel RD (2005) MSight: an image analysis software for liquid chromatography–mass spectrometry. Proteomics 5:2381–2384PubMedCrossRefGoogle Scholar
  17. 17.
    Hirosawa M, Hoshida M, Ishikawa M, Toya T (1993) MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming. Comput Appl Biosci 9:161–167PubMedGoogle Scholar
  18. 18.
    Haqqani AS, Kelly JF, Stanimirovic DB (2008) Quantitative protein profiling by mass spectrometry using label-free proteomics. Methods Mol Biol 439:241–256PubMedCrossRefGoogle Scholar
  19. 19.
    Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, Ideker T (2012) A travel guide to Cytoscape plugins. Nat Methods 9:1069–1076PubMedCrossRefGoogle Scholar
  20. 20.
    Barabasi AL, Oltvai ZN (2004) Network biology: understanding the cell’s functional organization. Nat Rev Genet 5:101–113PubMedCrossRefGoogle Scholar
  21. 21.
    Assfalg A, Erdfelder E (2012) CAML—maximum likelihood consensus analysis. Behav Res Methods 44:189–201PubMedCrossRefGoogle Scholar
  22. 22.
    bi-Haidar A, Kaur J, Maguitman A, Radivojac P, Rechtsteiner A, Verspoor K, Wang Z, Rocha LM (2008) Uncovering protein interaction in abstracts and text using a novel linear model and word proximity networks. Genome Biol 9(Suppl 2):S11CrossRefGoogle Scholar
  23. 23.
    Melnik O, Vardi Y, Zhang CH (2004) Mixed group ranks: preference and confidence in classifier combination. IEEE Trans Pattern Anal Mach Intell 26:973–981PubMedCrossRefGoogle Scholar
  24. 24.
    Haqqani AS, Hill JJ, Mullen J, Stanimirovic D (2011) Methods to study glycoproteins at the blood–brain barrier using mass spectrometry. In: Nag S (ed) Methods in molecular biology: the blood–brain and other neural barriers. The Humana Press, Totowa, NJ, pp 337–353CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Arsalan S. Haqqani
    • 1
  • Danica B. Stanimirovic
    • 1
  1. 1.Human Health Therapeutics PortfolioNational Research Council of CanadaOttawaCanada

Personalised recommendations